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Abstract: Background Hypertrophic cardiomyopathy (HCM) is associated with an increased risk of ad-
verse cardiac events. Beyond classic risk factors, relative myocardial ischaemia and succeeding myocardial
alterations, which can be detected using either contrast agents or parametric mapping in cardiovascular
magnetic resonance (CMR) imaging, have shown an impact on outcome in HCM. CMR may help to
risk stratify using parametric T2* mapping. Therefore, the aim of the present study was to evaluate
the association of T2* values or fibrosis with cardiovascular events in HCM. Methods The relationship
between T2* with supraventricular, ventricular arrhythmia or heart failure was retrospectively assessed
in 91 patients with HCM referred for CMR on a 1.5T MR imaging system. Fibrosis as a reference was
added to the model. Patients were subdivided into groups according to T2* value quartiles. Results
47 patients experienced an event of ventricular arrhythmia, 25 of atrial fibrillation/flutter and 17 of
heart failure. T2*฀28.7 ms yielded no association with ventricular events in the whole HCM cohort. T2*
of non-obstructive HCM showed a significant association with ventricular events in univariate analysis,
but not in multivariate analysis. For the combined endpoint of arrhythmic events, there was already
an association for the whole HCM cohort, but again only in univariate analyses. Fibrosis stayed the
strongest predictor in all analyses. There was no association for T2* and fibrosis with heart failure.
Conclusions Decreased T2* values by CMR only provide a small association with arrhythmic events in
HCM, especially in non-obstructive HCM. No information is added for heart failure.
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Key questions
What is already known about this subject?
 ► Beyond classic risk factors, relative myocardial isch-
aemia and succeeding myocardial alterations have 
shown an impact on outcome in hypertrophic car-
diomyopathy (HCM). These alterations can either be 
detected using contrast agents or parametric map-
ping in cardiovascular magnetic resonance (CMR) 
imaging. In particular, CMR T2* mapping can detect 
these alterations and may help to risk stratify car-
diovascular events in HCM.
What does this study add?
 ► In this study, the relationship between T2* with su-
praventricular, ventricular arrhythmia or heart fail-
ure was retrospectively assessed in 91 patients with 
HCM referred for CMR. Fibrosis as a reference was 
added to the model. Decreased T2* values by CMR 
only provide a small association with arrhythmic 
events in HCM, especially in non- obstructive HCM 
with T2* values ≤28.7 ms. No information is added 
for heart failure.
How might this impact on clinical practice?
 ► Myocardial fibrosis by late gadolinium enhancement 
remained the strongest predictor indicating that T2* 
mapping may only be used in certain clinical set-
tings. In this context, decreased T2* values by CMR 
may provide a small association with arrhythmic 
events in HCM, especially for non- obstructive HCM.
ABSTRACT
Background Hypertrophic cardiomyopathy (HCM) is 
associated with an increased risk of adverse cardiac 
events. Beyond classic risk factors, relative myocardial 
ischaemia and succeeding myocardial alterations, which 
can be detected using either contrast agents or parametric 
mapping in cardiovascular magnetic resonance (CMR) 
imaging, have shown an impact on outcome in HCM. 
CMR may help to risk stratify using parametric T2* 
mapping. Therefore, the aim of the present study was 
to evaluate the association of T2* values or fibrosis with 
cardiovascular events in HCM.
Methods The relationship between T2* with 
supraventricular, ventricular arrhythmia or heart failure 
was retrospectively assessed in 91 patients with HCM 
referred for CMR on a 1.5T MR imaging system. Fibrosis 
as a reference was added to the model. Patients were 
subdivided into groups according to T2* value quartiles.
Results 47 patients experienced an event of ventricular 
arrhythmia, 25 of atrial fibrillation/flutter and 17 of 
heart failure. T2*≤28.7 ms yielded no association with 
ventricular events in the whole HCM cohort. T2* of 
non- obstructive HCM showed a significant association 
with ventricular events in univariate analysis, but not 
in multivariate analysis. For the combined endpoint of 
arrhythmic events, there was already an association 
for the whole HCM cohort, but again only in univariate 
analyses. Fibrosis stayed the strongest predictor in all 
analyses. There was no association for T2* and fibrosis 
with heart failure.
Conclusions Decreased T2* values by CMR only provide 
a small association with arrhythmic events in HCM, 
especially in non- obstructive HCM. No information is 
added for heart failure.
BaCkgRound
Hypertrophic cardiomyopathy (HCM) is 
a frequent cause of sudden cardiac death 
(SCD).1–3 Despite a common macroscopic, 
morphological endpoint with increasing 
left ventricular mass (LVM) and wall thick-
ness, HCM is characterised by heteroge-
neous pathophysiological substrates.4 This 
heterogeneity can be triggered by myocar-
dial ischaemic reactions caused by a rela-
tive mismatch of myocardial demand and 
coronary blood supply.4–6 Over time, relative 
myocardial ischaemia is thought to trigger a 
varying degree of myocardial oedema, cell 
death, and fibrosis.
Although the disease may show a benign 
course, the ischaemic cascade in HCM shows 
an impact on prognosis.7 8 To determine the 
risk of future cardiovascular events, common 
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risk stratification models include a variety of markers, 
for example, severity of LV hypertrophy (LVH) or non- 
sustained ventricular tachycardia (nsVT).4 Although this 
model has proven useful in risk stratification, it does not 
identify all patients with HCM at risk. Cardiovascular 
magnetic resonance (CMR) has emerged as a diagnostic 
tool for the ongoing search of additional risk factors in 
order to improve risk stratification9 10 and recent inves-
tigations have revealed relative ischaemia and fibrosis 
as potential predictors to cardiovascular events in 
HCM.6 8 11 12
CMR is able to detect myocardial alterations and 
relative ischaemia using contrast agent and parametric 
mapping.6 13–15 In particular, T2* mapping has proven 
feasibility to detect ischaemic segments in extracardiac 
organs but also in myocardial infarction and coronary 
artery disease (CAD).15–21 Reduced T2* values have been 
described in patients with HCM potentially triggered 
through relative ischaemia.22 As relative ischaemia seems 
to be related to a worse prognosis, the aim of this study 
was to assess the relation of myocardial T2* mapping 
by CMR with the occurrence of arrhythmia or heart 
failure (HF) in patients with HCM. As known prognostic 
markers, fibrosis and troponin T were taken into the 
model for comparison.
MetHods
The study was conducted in accordance with the Decla-
ration of Helsinki and its later amendments. All data 
used for this study were acquired for clinical purposes 
and handled anonymously. This retrospective study had 
ethics committee approval of the Ethics Committee of 
the Canton of Zurich. Written informed consent was 
waived by the Institutional Review Board.
study population
In total, 91 patients (age 49.9±16.8 years) with HCM were 
retrospectively included in this study from June 2012 to 
May 2018. The patients were referred for clinical evalu-
ation in our hypertrophic cardiomyopathy outpatient 
clinic and diagnosed with the disease according to the 
2014 European Society of Cardiology (ESC) Guidelines4 
with otherwise unexplained LVH and/or a maximal 
wall thickness ≥15 mm. Forty- five patients (49%) had an 
obstructive form with significant left ventricular outflow 
tract (LVOT) obstruction with either a resting or provo-
cable gradient ≥30 mm Hg on transthoracic echocardiog-
raphy (TTE). Due to an influence of CAD on T2* values, 
patients with relevant CAD, determined by invasive cath-
eter coronary angiography or non- invasive imaging, were 
excluded.15 All patients with HCM underwent CMR. 
Clinical data were obtained by review of medical records. 
Patients were followed according to a specified care track 
with yearly ECG, blood work, TTE, Holter monitor and 
CMR every 3–5 years.
diagnostic criteria for study endpoints
Ventricular arrhythmias ranging from nsVT to SCD events 
and/or atrial fibrillation/flutter as well as HF were chosen 
as single or as a combined (arrhythmic) endpoint. Atrial 
fibrillation/flutter and ventricular arrhythmias were diag-
nosed either on resting ECG, Holter or during device 
interrogation. NsVTs were defined as ≥3 ventricular beats 
at a rate >100 bpm, sustained VT as duration of >30 s 
and SCD events as follows: unexpected sudden collapse 
within 1 hour from the onset of symptoms in patients 
with a previous stable clinical course.12 23 24 In addition, 
successful resuscitation from cardiac arrest or an appro-
priate intervention from an implantable cardioverter 
defibrillator (ICD) was regarded as SCD- equivalent. HF 
was defined as progression to New York Heart Association 
(NYHA) class III or IV in the absence of LVOT obstruc-
tion, left ventricular ejection fraction (LVEF) <50% or 
hospitalisation due to HF complications.8
Besides T2* values and fibrosis, troponin T was 
obtained as an additional parameter during routine 
examination around the time of the CMR and a value 
>0.014 ng/mL was considered elevated according to labo-
ratory standards.
Cardiovascular magnetic resonance
CMR was performed on a 1.5T MRI System (Achieva, 
Philips) using a five- channel phased- array coil. Func-
tional and geometric assessment was performed using 
balanced cine steady- state free precession (SSFP) images 
in standard long- axis geometries (two- chamber, three- 
chamber and four- chamber view) as well as in short- axis 
orientation with full ventricular coverage from base to 
apex (repetition time (TR)/echo time (TE)= 3.3/1.6 ms, 
flip angle (FA) = 60°, spatial resolution = 1.5×1.5×8 mm3, 
50 phases, two slices per breath- hold).15
T2* mapping was performed using a single breath- 
hold multiecho fast field- echo sequence in one short- 
axis midventricular slice at end- diastole (six echoes with 
shortest interecho spacing, TR: 13 ms, TE: 3 ms, flip angle 
35°, acquired spatial resolution 1.6×2.8×8 mm3, band-
width 781 Hz/pixel).15 If applicable (glomerular filtra-
tion rate >30 mL/min), gadolinium- based contrast agent 
(Gadovist, Bayer Healthcare) was administered at doses 
of 0.2 mmol/kg for late gadolinium- enhanced imaging 
(LGE). After 10 min, a three- dimensional gradient 
spoiled turbo fast- field- echo sequence with a non- 
selective 180° inversion pre- pulse was acquired at end- 
diastole with anatomical reference taken from balanced 
SSFP images.25
Postprocessing
Postprocessing was performed using commercial soft-
ware (IntelliSpace Portal, Philips). Short- axis and long- 
axis slices were analysed covering maximum end- diastolic 
interventricular septum thickness (IVS), left ventricular 
indexed end- diastolic volume (LVEDVi), LVEF and 
indexed LVM (LVMi).
T2* sequences were postprocessed according to recent 
guidelines as follows: a region of interest (ROI) was 
manually drawn at a midventricular level using a stan-
dardised ROI size (≈50 mm2) and visually avoiding partial 
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Figure 1 Placing of the ROI in a T2* map of a patients with 
T2* values below (A) and above (B) the fourth quartile. ROI, 
region of interest.
Table 1 Clinical (A) and CMR (B) baseline characteristics.
(A) Clinical All patients (n=91)
Age (years) 49.9±16.8
Male (%) 69 (76)
BSA (m2) 1.92±0.2
Family history of HCM, n(%) 32 (35)
Comorbidities   
  Diabetes, n(%) 5 (5)
  Hypertension, n(%) 27 (30)
  Hypercholesterolaemia, n(%) 22 (24)
  Renal insufficiency
  (GFR <60 mL/min), n(%)
9 (10)
  CAD, n(%) 0 (0)
  Class NYHA III- IV n(%) 12 (13)
(B) CMR All patients HOCM HNCM P value
LVEF (%) 65.3±8.6 67.0±6.5 63.6±10.0 0.116
IVS (mm) 19.6±4.0 20.9±3.6 18.3±3.9 <0.001
LVMi (g/m2) 85.0±29.6 90.8±29.4 79.3±29.4 0.032
LVEDVi (mL) 74.8±16.3 75.1±14.8 74.4±17.9 0.520
T2* (ms) 26.5±4.6 25.5±4.0 27.4±4.9 0.055
BSA, body surface area; CAD, coronary artery diseases; CMR, 
cardiovascular magnetic resonance; GFR, glomerular filtration 
rate; HCM, hypertrophic cardiomyopathy; HNCM, hypertrophic 
non- obstructive cardiomyopathy; HOCM, hypertrophic obstructive 
cardiomyopathy; IVS, interventricular septum; LVEDVi, left 
ventricular indexed end- diastolic volume; LVEF, left ventricular 
ejection fraction; LVMi, left ventricular indexed mass; NYHA, New 
York Heart Association.
volume effects at epicardial boarders as recommended 
in recent guidelines (figure 1).20 This has been shown 
feasible in previous studies in addition to avoid suscep-
tibility artefacts. For every ROI, the time constant of the 
signal intensity decay over all echoes was derived using a 
mono- exponential decay- curve. Afterwards, average T2* 
values and SD for this ROI were calculated and colour- 
coded using a spectral look- up table.
Fibrosis was assessed semiautomatically. Images with 
LGE were evaluated as follows: epicardial and endocar-
dial contours of the short- axis LGE images in every slice 
were drawn manually and the amount of fibrosis as a 
percentage of LVMi was calculated by using a full- width 
at half- maximum algorithm.26
statistical analysis
Statistical analysis was performed using SPSS (V.24.0). 
Unless otherwise stated, continuous variables are 
presented as mean±SD. Normal distribution was tested 
using the Shapiro- Wilk test for the comparison of CMR 
parameters between patients with (HOCM) and without 
(HNCM) outflow tract obstruction. Data between the two 
different groups were analysed by two- sided unpaired 
Student t- tests for normally distributed data and Mann- 
Whitney U- test for not normally distributed data. The χ2 
test or Fisher exact test was used to examine significant 
differences between nominal classifications.
In the first approach, the whole collective of patients 
with HCM was taken for statistical analyses. Afterwards 
patients were divided into HOCM and HNCM. T2* values 
were divided into quartiles (≤25%, 26%–50%, 51%–75%, 
>75%). Troponin T and the presence of fibrosis were 
entered into the model as well. To evaluate, whether 
T2* may predict the overall occurrence of the different 
arrhythmia groups or HF, univariate and multivariate 
binomial logistic regression models were calculated 
in which the event of arrhythmia or HF was entered as 
dependent variable and T2* values (either below the 
first quartile as cut- off or below the fourth quartile as cut- 
off), fibrosis and troponin T as independent variables. 
The multivariate model was constructed using a forward 
regression model with an entrance and stay criteria of 
p<0.1. For reasons of clarification, p values of excluded 
variables are reported as well.
Results
Patient population and CMR t2*
Clinical baseline characteristics are summarised in 
table 1A. The mean observation period was 1236.6±943.3 
days. Overall, 47 (49%) patients experienced ventricular 
events with 3 (6%) patients surviving a SCD (figure 2). 
Twenty- five (27%) patients exhibited atrial fibrillation/
flutter. Seventeen patients (19%) presented with HF of 
which 3 (3%) had an LVEF <50%, 3 (3%) were hospital-
ised due to HF complications and 11 (12%) progressed 
into NYHA class III.
CMR characteristics of all HCM are summarised in 
table 1B. According to quartile analyses, 23 patients 
presented with a T2* value ≤23.3 ms (first quartile), 23 
patients presented with T2* values between 23.4 and 
26.2 ms (second quartile), 23 patients presented with 
T2* values between 26.3 and 28.7 ms (third quartile) and 
22 patients presented with T2* values >28.7 ms (fourth 
quartile) (exemplary maps in figure 1). Troponin T was 
elevated in 33 (36%, 9 values missing) patients and fibrosis 
was present in 66 (73%) of all CMR analyses. Fibrosis 
extent ranged from 1% to 38% (mean: 10.1%±9.2%).
Ventricular arrhythmia
The incidence of ventricular arrhythmia in the different 
quartiles of HCM is summarised in table 2.
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Figure 2 Study diagram with numbers indicating the 
occurrence of ventricular, supraventricular events and heart 
failure. AF, atrial fibrillation/flutter; HNCM, hypertrophic 
non- obstructive cardiomyopathy; HOCM, hypertrophic 
obstructive cardiomyopathy; ICD, implantable cardioverter 
defibrillator; LVEF, left ventricularejection fraction; nsVT, non- 
sustained ventricular tachycardia; NYHA, New York Heart 
Association; SCD, sudden cardiac death; VT, ventricular 
fibrillation/tachycardia.








>28.7 ms P value
All VT/VF/SCD, n(%) 13/23 (57) 12/23 (52) 14/23 (61) 8/22 (36) 0.38
All AF, n(%) 6/23 (27) 7/23 (30) 8/23 (35) 4/22 (18) 0.64
HF, n(%) 3/23 (13) 1/23 (4) 8/23 (35) 5/22 (23) 0.05
AF, atrial fibrillation/flutter; HF, heart failure; SCD, sudden cardiac death; VF, ventricular fibrillation; VT, ventricular tachycardia.
Table 3 Results for the binomial logistic regression 
analysis of the relation between T2*, troponin T, fibrosis and 
ventricular events/SCD in the group of HCM (A) as well as in 
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HCM, hypertrophic cardiomyopathy; HNCM, hypertrophic non- 
obstructive cardiomyopathy; SCD, sudden cardiac death.
In univariate binomial regression calculations inde-
pendent from the onset of ventricular arrhythmia, only 
fibrosis and troponin T, but not T2*, were associated with 
an increased risk of arrhythmia (table 3A). In multivariate 
analysis, fibrosis stayed the only independent predictor 
(p=0.004, OR=5.29).
In a second approach, patients were divided into HOCM 
and HCM. According to the ESC Guidelines on HCM, 45 
patients (49%) had a diagnosis of HOCM.4 There was no 
significant difference in T2* values between both groups 
(table 1B).
Binomial regression showed that patients with HNCM 
with a T2*≤28.7 (p=0.033) or fibrosis (p=0.014) had the 
greatest association with ventricular events (table 3B). 
Fibrosis stayed the only independent predictor in multi-
variate analyses (p=0.039, OR=10.2).
For HOCM, neither T2*, fibrosis nor troponin T 
revealed a significant association with ventricular 
arrhythmias.
atrial fibrillation/flutter
The incidence and number of included patients into the 
subanalyses of atrial fibrillation/flutter are summarised 
in table 2. Neither the whole cohort, nor the division 
into HNCM or HOCM revealed a significant association 
between T2* values, fibrosis, troponin T and atrial fibril-
lation/flutter in regression analyses.
Combined arrhythmic endpoint
For a combined endpoint of ventricular and supraven-
tricular events, univariate binomial logistic regres-
sion calculations revealed an association of T2*≤28.7 
ms (p=0.047) or fibrosis (p=0.007) with an increased 
risk of arrhythmia (table 4A). In multivariate analysis, 
fibrosis stayed the only independent predictor (p=0.015, 
OR=3.59).
Dividing the whole cohort according to HOCM and 
HNCM, binomial regression showed that patients with 
HNCM with a T2*≤28.7 (p=0.032) or fibrosis (p=0.016) 
had the greatest association with arrhythmic events 
(table 4b). However, fibrosis stayed the only predictor in 
multivariate analyses (p=0.052, OR=5.73).
For HOCM, no parameter revealed a significant associ-
ation with the combined endpoint of arrhythmia.
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Table 5 Results in the whole group of HCM for the 
binomial regression analyses of the relation between T2*, 
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Table 4 Results for the binomial regression analyses of 
the relation between T2*, troponin T, fibrosis and ventricular 
events/atrial fibrillation/flutter as combined endpoint in the 
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HCM, hypertrophic cardiomyopathy; HOCM, hypertrophic 
cardiomyopathy.
Heart failure
The incidence of HF in the different quartiles of HCM is 
summarised in table 2. Although a significant difference 
between the T2* quartile groups was indicated, no signif-
icant influence of T2*, fibrosis or troponin T in the whole 
cohort as well as divided according to HOCM/HNCM 
could be detected (table 5).
disCussion
Although commonly used for predicting adverse cardi-
ovascular events, current risk stratification models for 
HCM using a combination of clinical and imaging 
parameters are limited in identifying all patients, mainly 
as a result of the heterogeneity of the disease.3 12 27 As 
adverse events may occur in patients with HCM that are 
considered at low risk, there is a need to identify addi-
tional markers.2
CMR is recommended a class IB indication in patients 
with HCM and interest has emerged to improve risk 
stratification models using CMR parameters.4 In this 
context, one focus has been on the cascade of myocar-
dial ischaemic reactions. The presence of relative isch-
aemia has already shown to influence the prognosis 
of patients with HCM on either arrhythmic events or 
HF.8 28 In CMR, myocardial ischaemia and fibrosis can 
be imaged using contrast agents or using parametric 
mapping on the basis of magnetic relaxation proper-
ties.14 29 In particular, T2* mapping is able to charac-
terise the relaxation of the transverse magnetisation that 
is influenced by macroscopic (inhomogeneities of the 
magnetic field) and mesoscopic (structure of the tissue) 
magnetic field inhomogeneities.14 20 In this context, 
reduced T2* values have already shown the potential to 
describe structural alterations suggestive of ischaemic 
alterations, collagen areas or haemorrhage in cardiac 
and extracardiac tissues.15 18 21 According to this, histo-
pathological substrates of T2* and a correlation of T2* 
to flow analyses have been studied.16 17 19 20 30 Recently, 
reduced T2* values have been described in a group of 
patients with HCM potentially triggered through relative 
ischaemia.22 Another explanation for the reduction of 
T2* values could be that in areas of reduced perfusion, 
oxymyoglobin and haemoglobin as oxygen suppliers are 
decreased, whereas deoxymyoglobin and haemoglobin 
are increased. In contrast to oxygenated proteins, deoxy-
genated proteins are paramagnetic and reduce local T2* 
values. However, further studies will have to confirm the 
potential substrates for a T2* reduction.
In the present study, patients with HCM showed 
a varying degree of myocardial T2* values, which 
supports previous studies that showed heterogeneity 
in myocardial ischaemic reactions.12 Therefore, indi-
vidual cut- offs to predict arrhythmic events could be 
chosen according to quartiles. T2* mapping in the 
present study was not designed to detect myocardial 
iron overload that can further decrease T2*-values with 
an impact on the prognosis of patients with thalassemia 
major. No further division below 23.4 ms was made.31
Only the endpoint of ventricular arrhythmia alone was 
associated with T2* values in patients with HNCM in univar-
iate analyses. Combining arrhythmic events, there was an 
association between T2* and arrhythmic events of the whole 
HCM cohort. None could be detected for HF. Assuming 
T2* values to be influenced by relative ischaemia, previous 
studies have already detected an association of abnormal T2 
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signal as a sign for myocardial damage and arrhythmia.32 33 
In general, the results of the additional parameter of fibrosis 
were in line with previous studies showing an increased 
risk of events for patients with fibrosis.12 28 34 One should 
note that fibrosis, which was measured covering the whole 
heart, stayed the strongest predictor for arrhythmic events 
in patients with HCM throughout univariate and multivar-
iate analyses. Whole heart coverage using T2* is not recom-
mended in recent guidelines due to susceptibility artefacts 
at the epicardial borders of the heart.20 As T2* has shown 
reduced values in patients with HCM and fibrosis, current 
analyses of the association of T2* with cardiac events in 
HCM possibly support results for fibrosis without the need 
for contrast agent, but with less clear results. This is further 
supported that T2* and fibrosis showed no linear correla-
tion. Therefore, T2* values may be of potential value in 
cases of doubt or when patients with HCM are not eligible 
for contrast administration.
Especially patients with HNCM exhibited an associ-
ation between T2* values and ventricular arrhythmia 
or a combined endpoint, but only in univariate anal-
yses. Taking conventional risk stratification models that 
include LV wall thickness and LVOT gradient, those 
patients would have been graded to be at lower risk.4 
However, the overall significance could have been 
hampered due to low numbers in the subgroups.
Comparing the patients below the third quartile in 
common risk stratification parameters, one should 
note that thickened IVS and HOCM occurrence were 
significantly higher in patients with reduced T2* 
values. However, T2* values did not show a correla-
tion to thickened IVS, elevated LVMi or age. As a 
consequence, T2* may potentially identify addi-
tional patients with a higher risk of arrhythmia that 
were considered at low risk for cardiac events using 
previous risk model estimations.4 35 It should be noted 
that higher T2* values do not preclude future cardiac 
events, suggesting further influencing factors that 
should be taken into account.8
The study was conducted as a retrospective, single- 
centre study. Therefore, the size of our study population, 
especially in subanalyses, must be acknowledged as one 
limitation and was the reason to only perform logistic 
regression. Prospective multicentre studies using longer 
follow- up periods and more patients should be used to 
further evaluate the influence of T2*.
Owing to our study design, patients with ICD or 
confirmed CAD had to be excluded, thereby potentially 
introducing some study bias.
Finally, LGE was not further subdivided according 
to the extent in % of affected LVMi as those data have 
already been published before.12
Perfusion sequences and parametric T1* mapping with 
extracellular volume measurements would have been of 
additional value to quantify relative ischaemia without 
the use of contrast agents. Nevertheless, LGE remains still 
one of the gold standards for the detection of fibrosis.
ConClusions
Decreased T2* values by CMR only provide a small 
association with arrhythmic events in HCM, especially 
for HNCM. However, within most analyses, myocardial 
fibrosis by LGE remained the strongest predictor indi-
cating that T2* may be used as additional marker in 
certain clinical settings.
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